[Histological changes in 20 hepatic fibrosis patients with chronic hepatitis B after recombinant human interferon-gamma treatment].
OBJECTIVE
To observe histological changes of hepatic fibrosis patients with chronic hepatitis B after recombinant human interferon-gamma treatment.


METHODS
Twenty hepatic fibrosis patients with chronic hepatitis B received rhIFN-gamma treatment at the dose of 1 MU intramuscularly daily for the first three months and every other day for the next six months. Liver biopsy was performed at the start of the therapy and the end of 9-month follow-up period respectively in all patients. All liver biopsy specimens were stained with hematoxylin-eosin and picro-sirius red. Modified Scheuer and Chevallier semi-quantitative scoring system was used to assess the results. In the meantime, serum hepatic fibrosis indices and serum biochemical examination were detected.


RESULTS
After 9 moths of treatment, the mean fibrosis score decreased from 11.24 +/- 5.34 to 8.67 +/- 4.16 (P<0.01), whereas the mean inflammation score decreased from 12.78 +/- 5.19 to 6.57 +/- 2.95 (P<0.01).


CONCLUSIONS
rhIFN-gamma showes a beneficial effect on hepatic fibrosis patients with chronic hepatitis B.
Du
X
X
Beilun Zongrui Hospital, Ningbo 315806, China.
Weng
H
H
Cai
W
W
D000293:Adolescent; D000328:Adult; D000368:Aged; D005260:Female; D019694:Hepatitis B, Chronic / Q000150:complications / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D006801:Humans; D007371:Interferon-gamma / Q000627:therapeutic use*; D008103:Liver Cirrhosis / Q000150:complications / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins / Q000627:therapeutic use
D011994:Recombinant Proteins; D007371:Interferon-gamma